Live
- OEC to prepare coastal protection plan for Odisha
- District SP inspects Kerameri police station
- Women urged to become self-reliant
- Indiramma House Survey should be done transparently: Veerlapalli
- Ponnam urges KGBV teachers to call off strike
- India, Pak in same group; to clash on Feb 23 in Dubai
- India, Pak in same group; to clash on Feb 23 in Dubai
- Kareena reveals her favourite Shyam Benegal film featuring sister Karisma
- A day with Collector Jeebanananda Mohanty
- Odisha signs pact to operate hydrogen-powered bus
DRL, MSN get license to launch Covid drug
DRL, MSN get license to launch Covid drug
City-based Dr Reddy's Laboratories (DRL) and MSN Laboratories along with Ahmedabad-based Torrent Pharmaceuticals have entered into a royalty free, non-exclusive, voluntary license agreement with US-based pharma firm Eli Lilly for manufacture and commercialisation of ‘baricitinib’ drug for the treatment of Covid-19 in India.
Hyderabad: City-based Dr Reddy's Laboratories (DRL) and MSN Laboratories along with Ahmedabad-based Torrent Pharmaceuticals have entered into a royalty free, non-exclusive, voluntary license agreement with US-based pharma firm Eli Lilly for manufacture and commercialisation of 'baricitinib' drug for the treatment of Covid-19 in India.
The drug baricitinib has been granted a restriDRL, MSN get license to launch Covid drugcted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company's existing range of Covid-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine. Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy's Laboratories, said: "From the start, we have been determined to explore every possible avenue against Covid-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India." Speaking about the collaboration with Eli Lilly, MSN Reddy, CMD of MSN Group said: "This is a landmark milestone in India's fight against Covid-19 and will thus help in increasing the availability and affordability of baricitinib. We will be launching the product under the brand name Baridoz in two strengths 2 mg and 4mg."
